Stockholders approve amended stock purchase plan adding 125,000 shares at 2023 annual meeting

Decoy Therapeutics Inc.

All three Class II director nominees (David Arthur, Bruce McCreedy, Jonathan Lieber) elected with over 267,000 votes each.
Amended ESPP approved: reserve increased by 125,000 shares, with annual automatic increase (2% or 75k shares) through 2028.
Non-binding advisory vote on executive compensation approved with 216,044 for, 85,774 against.
Ratification of Ernst & Young as auditor for FY2023 approved with 913,353 for.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Decoy Therapeutics Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-14 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

3. Proposal to provide a non-binding advisory vote on the compensation of the Company’s named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 216,044 85,774 12,655 727,170

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Decoy Therapeutics Inc. shareholders approved Election of three Class II directors at the 2023-06-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

1. Proposal to elect three Class II directors to serve until the 2026 annual meeting or until their successors are duly elected and qualified: Nominees Votes For Votes Against Abstentions Broker Non-Votes David J. Arthur 270,248 632 43,593 727,170 Bruce J. McCreedy 267,578 641 46,254 727,170 Jonathan Lieber 269,684 547 44,242 727,170

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Decoy Therapeutics Inc. shareholders approved Approval of Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan at the 2023-06-14 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

2. Proposal to approve the Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan: Votes For Votes Against Abstentions Broker Non-Votes 224,289 74,630 15,554 727,170

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Decoy Therapeutics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

4. Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 913,353 103,072 25,218

View on SEC.gov

289 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-23-000055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.